Analyst Price Targets — CRAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2024 3:24 pm | Kevin Steinke | Barrington | $194.00 | $154.25 | TheFly | Charles River Associates price target raised to $194 from $186 at Barrington |
| August 8, 2022 10:44 am | Kevin Steinke | Barrington | $120.00 | $94.53 | TheFly | CRA International price target raised to $120 from $115 at Barrington |
Latest News for CRAI
Investors need to pay close attention to CRAI stock based on the movements in the options market lately.
Charles River Associates' global talent network, cross-border expertise, and rising dividends and buybacks support long-term growth and enhance investor appeal.
PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access…
CRAI benefits from rising demand for specialized advisory services, but AI, talent costs and fierce competition pose risks.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRAI.
U.S. House Trading
No House trades found for CRAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.